+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Systemic Sclerosis (Scleroderma) (Immunology) - Drugs in Development, 2021

  • PDF Icon

    Drug Pipelines

  • March 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5331175
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis - Drugs in Development, 2021, provides an overview of the Systemic Sclerosis (Immunology) pipeline landscape.

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Sclerosis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 19, 11, 2, 40 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Systemic Sclerosis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Sclerosis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Sclerosis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Immunology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Systemic Sclerosis (Scleroderma) - Overview
  • Systemic Sclerosis (Scleroderma) - Therapeutics Development
  • Systemic Sclerosis (Scleroderma) - Therapeutics Assessment
  • Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development
  • Systemic Sclerosis (Scleroderma) - Drug Profiles
  • Systemic Sclerosis (Scleroderma) - Dormant Projects
  • Systemic Sclerosis (Scleroderma) - Discontinued Products
  • Systemic Sclerosis (Scleroderma) - Product Development Milestones
  • Appendix

List of Tables
  • Number of Products under Development for Systemic Sclerosis (Scleroderma), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Acceleron Pharma Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Accuitis Pharmaceuticals Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by AKL Research and Development Ltd, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Allysta Pharmaceuticals Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Amgen Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by AnaMar AB, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals LLC, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Aryogen Pharmed Co, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by AstraZeneca Plc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Atlantic Healthcare Plc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Aurora Research Institute LLC, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Avotres Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Biogen Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Biomendics LLC, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Blade Therapeutics Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by BriaCell Therapeutics Corp, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Co, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Cantargia AB, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Castle Creek Biosciences Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Celdara Medical LLC, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Centessa Pharmaceuticals Ltd, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Certa Therapeutics Pty Ltd, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by ChemomAb Ltd, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Chugai Pharmaceutical Co Ltd, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Civi Biopharma Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by CohBar Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Corbus Pharmaceuticals Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by CSL Ltd, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Cumberland Pharmaceuticals Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Cureveda LLC, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by D&D Pharmatech Co Ltd, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Emerald Health Sciences Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Ergon Pharmaceuticals LLC, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Foresee Pharmaceuticals Co Ltd, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Fresenius Kabi SwissBioSim GmbH, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Galapagos NV, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Galecto Biotech ApS, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by GenKyoTex SA, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Genmab AS, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Gilead Sciences Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by GNI Group Ltd, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by H. Lundbeck AS, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Horizon Therapeutics Plc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by iBio Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Ichnos Sciences Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Iltoo Pharma, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by ImmuneMed Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Johnson & Johnson, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Kadmon Corp LLC, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Leadiant Biosciences Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Link Genomics Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Luminary Therapeutics Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by MDI Therapeutics Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Mitsubishi Tanabe Pharma Corp, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Ono Pharmaceutical Co Ltd, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Opsidio LLC, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Panorama Research Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Patagonia Pharmaceuticals LLC, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by PDX Pharmaceuticals LLC, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Pfizer Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Processa Pharmaceuticals Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by RadBio, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Regeneron Pharmaceuticals Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Resolys Bio Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Ribomic Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Riptide Bioscience Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Samumed LLC, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Seagen Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Signablok Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Talaris Therapeutics Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Timber Pharmaceuticals Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by TRACON Pharmaceuticals Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Tvardi Therapeutics Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Unity Biotechnology Inc, 2021
  • Systemic Sclerosis (Scleroderma) - Pipeline by Vicore Pharma AB, 2021
  • Systemic Sclerosis (Scleroderma) - Dormant Projects, 2021
  • Systemic Sclerosis (Scleroderma) - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Systemic Sclerosis (Scleroderma), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Acceleron Pharma Inc
  • Accuitis Pharmaceuticals Inc
  • AKL Research and Development Ltd
  • Allysta Pharmaceuticals Inc
  • Amgen Inc
  • AnaMar AB
  • arGentis Pharmaceuticals LLC
  • Aryogen Pharmed Co
  • AstraZeneca Plc
  • Atlantic Healthcare Plc
  • Aurora Research Institute LLC
  • Avotres Inc
  • Biogen Inc
  • Biomendics LLC
  • Blade Therapeutics Inc
  • BriaCell Therapeutics Corp
  • Bristol-Myers Squibb Co
  • Cantargia AB
  • Castle Creek Biosciences Inc
  • Celdara Medical LLC
  • Centessa Pharmaceuticals Ltd
  • Certa Therapeutics Pty Ltd
  • ChemomAb Ltd
  • Chugai Pharmaceutical Co Ltd
  • Civi Biopharma Inc
  • CohBar Inc
  • Corbus Pharmaceuticals Inc
  • CSL Ltd
  • Cumberland Pharmaceuticals Inc
  • Cureveda LLC
  • D&D Pharmatech Co Ltd
  • Emerald Health Sciences Inc
  • Ergon Pharmaceuticals LLC
  • F. Hoffmann-La Roche Ltd
  • Foresee Pharmaceuticals Co Ltd
  • Fresenius Kabi SwissBioSim GmbH
  • Galapagos NV
  • Galecto Biotech ApS
  • GenKyoTex SA
  • Genmab AS
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • GNI Group Ltd
  • H. Lundbeck AS
  • Horizon Therapeutics Plc
  • iBio Inc
  • Ichnos Sciences Inc
  • Iltoo Pharma
  • ImmuneMed Inc
  • Johnson & Johnson
  • Kadmon Corp LLC
  • Leadiant Biosciences Inc
  • Link Genomics Inc
  • Luminary Therapeutics Inc
  • MDI Therapeutics Inc
  • Mitsubishi Tanabe Pharma Corp
  • Ono Pharmaceutical Co Ltd
  • Opsidio LLC
  • Panorama Research Inc
  • Patagonia Pharmaceuticals LLC
  • PDX Pharmaceuticals LLC
  • Peptinov SAS
  • Pfizer Inc
  • Processa Pharmaceuticals Inc
  • RadBio
  • Regeneron Pharmaceuticals Inc
  • Resolys Bio Inc
  • Ribomic Inc
  • Riptide Bioscience Inc
  • Samumed LLC
  • Seagen Inc
  • Signablok Inc
  • Takeda Pharmaceutical Co Ltd
  • Talaris Therapeutics Inc
  • Timber Pharmaceuticals Inc
  • TRACON Pharmaceuticals Inc
  • Tvardi Therapeutics Inc
  • Unity Biotechnology Inc
  • Vicore Pharma AB